Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: ALXN1820 in Sickle Cell Disease
NCT05565092Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tarperprumig in sickle cell disease (SCD), sponsored by Alexion Pharmaceuticals. Started Feb 2023; status: terminated.
02
Drugs
tarperprumig
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05565092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565092.